SCHEMBL17628504

SCHEMBL17628504

O=S(=O)(Cl)c1ccc2ccccc2c1-c1cccc2ccccc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DNMT1 P26358 1/20 0.47
TYMP P19971 1/20 0.43
MEN1 O00255 1/20 0.42
ALDH1A1 P00352 1/20 0.42
MAPT P10636 1/20 0.42
RAB9A P51151 1/20 0.42
KMT2A Q03164 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
CA1 P00915 6/20 0.42
CA2 P00918 6/20 0.42
CA9 Q16790 6/20 0.42
CA12 O43570 5/20 0.41
PAX8 Q06710 1/20 0.41
CES1 P23141 2/20 0.40
PTPN1 P18031 1/20 0.40
GPR84 Q9NQS5 1/20 0.40
HPRT1 P00492 1/20 0.39
NSD2 O96028 1/20 0.38
OPRM1 P35372 1/20 0.38
OPRD1 P41143 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29740512 0.83 DNMT1 (0.47) DNMT1TYMPMEN1ALDH1A1MAPT
SCHEMBL27844249 0.83 CA1 (0.59) DNMT1MEN1ALDH1A1MAPTRAB9A
SCHEMBL3909203 0.82 CA1 (0.52) DNMT1TYMPMEN1KMT2ACA1
Hydrochloric Acid SCHEMBL28180680 0.81 CTRB1 (0.49) DNMT1TYMPMEN1ALDH1A1MAPT
SCHEMBL7332420 0.77 CA1 (0.42) DNMT1MAPTCA1CA2CA9
SCHEMBL29410608 0.75 DNMT1 (0.59) DNMT1TYMPMEN1ALDH1A1MAPT
SCHEMBL57524 0.75 CA1 (0.63) MEN1ALDH1A1KMT2ACA1CA2
SCHEMBL29787010 0.75 DNMT1 (0.59) DNMT1TYMPMEN1ALDH1A1MAPT
SCHEMBL31605318 0.75 CA1 (0.63) MEN1ALDH1A1KMT2ACA1CA2
SCHEMBL196007 0.75 DNMT1 (0.59) DNMT1TYMPMEN1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3004065-B1 METHOD FOR PRODUCING PYRIDAZINE COMPOUND SUMITOMO CHEMICAL CO (JP) 2017-10-18 EP disclosed
US-9732042-B2 Method for producing pyridazine compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-08-15 US disclosed
EP-3004065-A1 METHOD FOR PRODUCING PYRIDAZINE COMPOUND Sumitomo Chemical Company, Limited (JP) 2016-04-13 EP disclosed
US-20160090363-A1 METHOD FOR PRODUCING PYRIDAZINE COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-03-31 US disclosed
CN-105228987-A For the preparation of the method for pyridazine compound SUMITOMO CHEMICAL CO 2016-01-06 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160090363-A1 METHOD FOR PRODUCING PYRIDAZINE COMPOUND PLP2, PNPO, CBR3 DNMT1 346/4885TYMP 394/4885MEN1 1621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.